ABUS vs OMC · P/E 5.4, rev $6.2M vs rev $17.27B
Arbutus Biopharma Corp (ABUS) versus Omnicom Group Inc (OMC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Omnicom Group Inc (OMC) is a advertising agencies company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported OMC revenue for 2025-12-31 was $17.27B. Net income was -$54.5M. Revenue was up 10.1% from 2024-12-31 to 2025-12-31. OMC currently screens at market cap $21.75B.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. OMC currently screens at market cap $21.75B.
Not investment advice. Open the ABUS and OMC stock pages for the full models.
Not investment advice.